Any pupil of biotech will tell you: One eyebrow-raising initial public offering does not an IPO wave make. Still, observers held hopes that if Eyetech Pharmaceuticals Inc. came through with a solid pricing and decent after-market performance, more of the pending IPOs might follow suit.

With generic competition in Europe looming on the horizon, industry powerhouse Amgen Inc. once again reported strong earnings, thanks largely to the company's erythropoietin (EPO) franchise. (BioWorld Today)